New Japanese Covid/PMX Study - results in 60 days or less? Efficacy and Safety of Direct Hemoperfusion Using Polymyxin B-Immobilized Polystyrene Column for Patients With COVID-19: Protocol for an Exploratory Study
Results:The study period is scheduled from September 28, 2020, through April 30, 2023. Patient enrollment was scheduled from the Japan Registry of Clinical Trials publication for March 31, 2022. Data fixation is scheduled for October 2022, with the publication of the results by March 2023.
Conclusions:From a clinical perspective, PMX-DHP is expected to become an adjunctive therapy to address unmet medical needs and prevent the exacerbation from moderate to severe acute respiratory distress syndrome in COVID-19 cases.
https://www.researchprotocols.org/2022/11/e37426
_______________________________________________
I wonder what a successful study might do to the potential market size for PMX given that Covid is here to stay, and new hospital treatments are needed for severe cases ?
MM